Importantly, the druggable evaluation revealed that ACHE and FN1 were targets of currently approved drugs, highlighting the importance of existing medications that could potentially be repurposed or serve as the basis for the development of new treatments for osteoporosis. Here, ACHE is linked to osteoporosis.